Adrenoleukodystrophy Market Growth Is Soaring Owing to Several Key Pharma Players Tapping Opportunities

August 14 16:02 2020
Adrenoleukodystrophy Market Growth Is Soaring Owing to Several Key Pharma Players Tapping Opportunities

Adrenoleukodystrophy Market Size | ALD Market Size
The Adrenoleukodystrophy market size was USD 523.26 million in 2017 for the US.
The ALD market is driven by key pharma players such as Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, and others are proactively focusing on advancing ALD pipeline, increasing prevalence, and increased R&D in the domain.

DelveInsight’s “Adrenoleukodystrophy – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Adrenoleukodystrophy, historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Adrenoleukodystrophy: Disease Overview

Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands.

 

Know more about report offerings: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market

 

Adrenoleukodystrophy Epidemiology Analysis

The epidemiology section covers the 7MM countries, the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from the year 2017 to 2030. 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented into:

  • Total Adrenoleukodystrophy Prevalent Population
  • Gender-specific Adrenoleukodystrophy Prevalence
  • Gender-specific Diagnosed Adrenoleukodystrophy Prevalence
  • Type-specific Diagnosed Prevalence of ALD in Males

However, rare, Adrenoleukodystrophy is a devastating disease and has no cure.

 

Request for free sample pages: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market

 

Adrenoleukodystrophy treatment market comprises of general supportive care and symptomatic treatment, primarily managed by hormone replacement therapy, dietary therapy with Lorenzo’s oil, and Hematopoietic stem cell transplantation.

Adrenoleukodystrophy Market Analysis

The Adrenoleukodystrophy market report provides current treatment practices, emerging drugs, Adrenoleukodystrophy market share of the individual therapies, current and forecasted Adrenoleukodystrophy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Adrenoleukodystrophy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Key Highlights:

  • The market size for ALD was USD 523.26 million in 2017 for the US.
  • The ALD market is driven by key pharma players such as Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, and others are proactively focusing on advancing ALD pipeline, increasing prevalence, and increased R&D in the domain.
  • A noticeable growth can be seen in the year 2022 owing to the launch of Lenti-D (Gene therapy; Bluebird Bio), and Leriglitazone (MIN-102) (Minoryx Therapeutics).

 

Read more: https://www.delveinsight.com/blog/adrenoleukodystrophy-market-size/

 

Pipeline Therapies

  • Lenti D: bluebird bio
  • Leriglitazone: Minoryx Therapeutics
  • MGTA-456: Magenta Therapeutics
  • MD1003: MedDay Pharmaceuticals
  • OP-101: Orpheris
  • SOM1201: SOM Biotech

 

Visit to know more: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market

 

Table of Contents

1. Key Insights

2. Adrenoleukodystrophy (ALD): Market Overview at a Glance

3. Adrenoleukodystrophy: Disease Background and Overview

4. Epidemiology and Patient Population

5. United States Epidemiology

6. EU5 Epidemiology

7. Japan Epidemiology

8. Current Treatment and Medical Practices

9. Unmet Needs

10. Emerging Therapies

11. Failed Therapy

12. Adrenoleukodystrophy (ALD): 7MM Market Analysis

13. 7MM: Market Outlook

14. United States

15. EU-5 countries

16. Japan

17. Market Drivers

18. Market Barriers

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Browse through our vast repository from here.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/